Evidence map›Paper›PMID 36622469›Full record

Trial reportInternational journal of clinical oncology2023

Long-term results of a phase 2 study of neoadjuvant chemotherapy with molecularly targeted agents for locally advanced rectal cancer.

Ryuhei Aoyama, Koya Hida, Suguru Hasegawa, Takashi Yamaguchi, Dai Manaka, Shigeru Kato, Masahiro Yamada, Satoshi Yamanokuchi, Takahisa Kyogoku, Akiyoshi Kanazawa and 5 more

Abstract readClinical Trial, Phase II
PubMed Publisher
In one paragraph

Trial report in International journal of clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 9 institutions in 1 country.

Ryuhei AoyamaDepartment of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Koya HidaDepartment of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan. hidakoya@kuhp.kyoto-u.ac.jp.ORCID http://orcid.org/0000-0001-7210-7075
Suguru HasegawaDepartment of Gastroenterological Surgery, Fukuoka University, Fukuoka, Japan.
Takashi YamaguchiDepartment of Surgery, Kyoto Medical Center, Kyoto, Japan.
Dai ManakaDepartment of Surgery, Kyoto Katsura Hospital, Kyoto, Japan.
Shigeru KatoDepartment of Gastrointestinal Surgery, Tenri Yorozu Hospital, Nara, Japan.
Masahiro YamadaDepartment of Surgery, Shiga General Hospital, Shiga, Japan.
Satoshi YamanokuchiDepartment of Surgery, Osaka Red Cross Hospital, Osaka, Japan.
Takahisa KyogokuDepartment of Surgery, Nishi-Kobe Medical Center, Kobe, Japan.
Akiyoshi KanazawaDepartment of Gastroenterological Surgery and Oncology, Kitano Hospital Medical Research Institute, Osaka, Japan.
Kenji KawadaDepartment of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Takashi SakamotoDepartment of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Saori GotoDepartment of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Yoshiharu SakaiDepartment of Surgery, Osaka Red Cross Hospital, Osaka, Japan.
Kazutaka ObamaDepartment of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Kyoto University · JPOsaka Red Cross Hospital · JPFukuoka University · JPKitano Hospital · JPKobe Medical Center · JPKyoto Katsura Hospital · JPKyoto Medical Center · JPShiga Medical Center · JPTenri Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe previously reported the feasibility and efficacy of neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer. Here, we report the results of a long-term follow-up study.

methodsThis was a multi-institutional, prospective phase 2 study of patients with locally advanced rectal cancer. Patients received neoadjuvant chemotherapy with molecularly targeted agents before undergoing total mesorectal excision. Six cycles of modified FOLFOX (mFOLFOX6) with bevacizumab were administered to KRAS-mutant patients, and mFOLFOX6 with cetuximab was administered to KRAS-wild-type patients. Here, we report the secondary end points of overall survival, relapse-free survival, and local recurrence rate.

resultsSixty patients were enrolled in this study. R0 resection was achieved in 98.3% (59/60) patients, and pathological complete response was achieved in 16.7% (10/60) patients. After a median follow-up of 5.4 years, the 5 year overall survival was 81.6%, the 5 year relapse-free survival was 71.7%, and the 5 year local recurrence rate was 12.6%. None of the patients who achieved pathological complete response developed recurrence within 5 years.

conclusionsThe use of molecularly targeted agents in the neoadjuvant setting for locally advanced rectal cancer has an acceptable prognosis.

Indexed as

Antineoplastic AgentsRectal NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsFluorouracilFollow-Up StudiesHumansNeoadjuvant TherapyNeoplasm Recurrence, LocalNeoplasm StagingProspective StudiesProto-Oncogene Proteins p21(ras)Antineoplastic AgentsFluorouracilProto-Oncogene Proteins p21(ras)Molecularly targeted therapyNeoadjuvant therapyRectal neoplasmsSurvival

Identifiers

PMID36622469
OpenAlexW4313829942

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.